Rounding up five deals in the pharma commercialization segment, and delving into trends driving that activity; a discussion with 888 Midas’ Ross Walker on the firm’s strategy for investing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback